NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 14 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Sai Life Sciences Q2 FY27 கான்கால்: வருவாய் 23% YoY உயர்வு, H1 மூலதனச் செலவு ₹621 கோடியை எட்டியது
Sai Life Sciences தனது Q2 FY27 வருவாய் கான்கால் டிரான்ஸ்கிரிப்டை வெளியிட்டுள்ளது. இக்காலாண்டில் வருவாய் 23% YoY உயர்ந்தது; CDMO 20% உயர்வும், CRO சேவைகள் 28% அதிகரிப்பும் இதற்குக் காரணம். Q2 மற்றும் H1 FY27 ஆகிய இரண்டிலும் EBITDA மார்ஜின் 28% ஆக இருந்தது. H2 பருவகாலரீதியாக வலுவாக இருக்கும் என நிர்வாகம் முன்னறிவித்துள்ளது. H1 FY27இல் ₹621 கோடி மூலதனச் செலவு செய்யப்பட்டது (இதில் Q2இல் ₹358 கோடி அடங்கும்). முழு ஆண்டுக்கான ₹1,100–1,300 கோடி மூலதனத் திட்டத்தை (TTM வருவாயில் ~54%) நோக்கி நிறுவனம் முன்னேறுகிறது. செயல்பாட்டில், ஒரு மூலக்கூறு late-phase நிலையிலிருந்து வணிக உற்பத்திக்கு மாறியுள்ளது. திட்டமிடப்பட்ட இரண்டு 225 KL உற்பத்தி பிளாக்குகளில் ஒன்று தயாராக உள்ளது.
உச்சம் நம்பிக்கை
என்ன மாறியதுநவம்பர் 6, 2026 அன்று நடைபெற்ற Q2 FY27 வருவாய் கான்கால் குறித்த முறையான டிரான்ஸ்கிரிப்ட் சமர்ப்பிக்கப்பட்டது. இதில் பிரிவு வாரியான வளர்ச்சி அளவீடுகள், பைப்லைன் மாற்றங்கள் மற்றும் மூலதனச் செலவின் நடைமுறை ஆகியவை வெளியிடப்பட்டன.
ஏன் இது முக்கியம்FY27க்கான ₹1,100–1,300 கோடி திட்டம் மற்றும் TTM வருவாயான ₹2,239 கோடியுடன் ஒப்பிடும்போது, வேகமான உற்பத்தித் திறன் சேர்ப்பு குறித்த விரிவான செயல்பாட்டுத் தெளிவை இது தருகிறது. உள்ளீட்டுச் செலவு அழுத்தங்களுக்கு மத்தியிலும் 28% EBITDA மார்ஜின் தொடர்வதை இது உறுதிப்படுத்துகிறது.
Q2 FY27 வருவாய் வளர்ச்சி: 23% YoYQ2 FY27 EBITDA மார்ஜின்: 28%H1 FY27 மூலதனச் செலவு: INR621 கோடிFY27 மூலதனச் செலவு வழிகாட்டுதல்: INR1,100 கோடி-INR1,300 கோடிFY27 மூலதனச் செலவு vs TTM வருவாய்: ~54%உற்பத்தி பிளாக் சேர்ப்பு: 225 KL each (two blocks)
📅 குறுகிய காலம்நிறுவனத்தின் வருவாய் டிரான்ஸ்கிரிப்ட் வலுவான செயல்பாட்டு நடைமுறையையும், இரண்டாம் பாதி வலுவாக இருக்கும் என்ற நிர்வாகத்தின் எதிர்பார்ப்பையும் உறுதிப்படுத்துகிறது; எனினும் நடைபெற்று வரும் விரிவாக்கங்களை செயல்படுத்துவதில்தான் சந்தையின் கவனம் இருக்கும்.
📈 நீண்ட காலம்கண்டுபிடிப்பிலிருந்து உற்பத்தி வரையிலான ஒருங்கிணைப்பும், பெப்டைடுகள்/ஒலிகோநியூக்ளியோடைடுகள் போன்ற புதிய மாடலிட்டிகளில் விரிவாக்கமும், பெரிய அளவிலான மூலதனச் செலவும் சேர்ந்து நீண்டகால CRDMO வளர்ச்சிக்கு ஆதரவளிக்கின்றன.
⚠ அபாய எச்சரிக்கைகள்
இரண்டாவது 225 KL உற்பத்தி பிளாக்கின் கமிஷனிங் தாமதம் (Q4 FY27இலிருந்து Q3 FY28க்கு மாற்றம்)
மத்திய கிழக்கு புவிசார் அரசியல் பதட்டங்களால் மூலப்பொருள் மற்றும் சால்வென்ட் விலை உயர்வு
👀 கவனிக்க வேண்டியவை
முடிவடைந்த 225 KL பிளாக்கின் கமிஷனிங் மைல்கற்கள் மற்றும் வணிக அளவிலான விரிவாக்கத்தைக் கண்காணியுங்கள்; மத்திய கிழக்கு விநியோகச் சங்கிலி அழுத்தங்களுக்கு மத்தியில் மூலப்பொருள் செலவு மீட்பு வழிமுறைகளையும் கவனியுங்கள்.
SAILIFE Reports Q2 FY27 Revenue Up 23% YoY to ₹659 Cr, Capex Plan at ₹1,100-1,300 Cr
Sai Life Sciences released its Q2 and H1 FY27 investor presentation, reporting consolidated quarterly revenue growth of 23% YoY to ₹659 crore. EBITDA for Q2 FY27 stood at ₹187 crore (up 20% YoY) with an EBITDA margin of 28%, while PAT increased 17% YoY to ₹98 crore. For H1 FY27, revenue reached ₹1,213 crore and PAT rose 19% to ₹172 crore. The company incurred ₹621 crore in capex during H1 FY27 (representing ~28% of TTM revenue) and remains on track for an annual capex target of ₹1,100 to ₹1,300 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுSai Life Sciences published its earnings presentation for Q2 and H1 FY27 detailing financial performance and business expansion metrics.
ஏன் இது முக்கியம்Demonstrates continued double-digit growth and stable 28% EBITDA margins while executing an aggressive capex plan of ₹1,100-1,300 crore (~50-58% of TTM revenue) to scale its CRDMO offerings.
📅 குறுகிய காலம்Market focus will center on earnings call insights regarding second-half demand, operationalization of integrated pharma collaborations, and debt/cash flow impacts of the heavy capex cycle.
📈 நீண்ட காலம்Structural tailwinds remain intact as the company expands from early-stage discovery into late-phase CDMO projects with global innovators, supported by significant asset expansion.
⚠ அபாய எச்சரிக்கைகள்
High ongoing capital expenditure (₹1,100-1,300 Cr projected for FY27) could increase short-term debt and depreciation drag if ramp-up lags
Short-term borrowings rose to ₹418 Cr in Sep 2026 from ₹75 Cr in Mar 2026
👀 கவனிக்க வேண்டியவை
Track the ramp-up of new capacity additions, commercialization timelines of late-phase pipeline molecules, and management commentary in the earnings call scheduled for November 6, 2026.
12% Revenue Growth in Q1 FY27; <₹300 Cr Peptide Expansion Planned by 2028
Sai Life Sciences reported a 12% YoY revenue growth for Q1 FY27, led by a robust 26% growth in the CRO segment. The company is transitioning from a small molecule specialist to a multi-modality CRDMO, with a new peptide manufacturing facility planned for 2028 involving an investment of less than ₹300 crore (approx. 12% of current Net Worth). Management expects a stronger H2 FY27 as new capacity expansions go live. The company maintains deep relationships, currently serving 19 of the top 25 global pharmaceutical firms.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has detailed its strategic shift toward multi-modality services, including Peptides, ADCs, and Formulations, while confirming a ₹300 crore capex plan for commercial peptide manufacturing.
ஏன் இது முக்கியம்Moving into high-value modalities like peptides and ADCs (Antibody-Drug Conjugates) allows the company to capture a larger share of the global pharma R&D spend and improves long-term margin potential.
📅 குறுகிய காலம்The outlook for the next few months is positive based on management's guidance for a stronger H2 FY27 and the upcoming launch of the formulation business.
📈 நீண்ட காலம்The structural shift toward becoming a multi-modality CRDMO by 2028 could significantly re-rate the business if execution on the peptide and ADC facilities remains on track.
⚠ அபாய எச்சரிக்கைகள்
Execution risk for the 2028 greenfield facility
Volatility in global biotech funding impacting CRO demand
Potential margin pressure during the initial ramp-up of new capacities
👀 கவனிக்க வேண்டியவை
Monitor the execution timeline of the new peptide facility and the operational launch of the formulation segment within the next two quarters. Watch for margin stability as the company ramps up new capacities in H2 FY27.
Q1 FY27 PAT up 22% to ₹73 Cr; Revenue grows 12% to ₹554 Cr with strong CRO momentum
Sai Life Sciences reported a steady Q1 FY27 with revenue growing 12% YoY to ₹554 Cr, led by a robust 24% growth in the CRO (Discovery) segment. Profitability improved significantly as PAT rose 22% YoY to ₹73 Cr, and EBITDA margins expanded to 27% from 25% in the previous year. The company continues its heavy investment phase, incurring ₹263 Cr in capex during the quarter (approx. 12% of TTM revenue). Management maintained its long-term revenue growth guidance of 15-20% and EBITDA margin targets of 28-30%.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned into FY27 with improved margins and strong growth in its Discovery (CRO) business, despite a slight sequential dip in revenue from Q4 FY26.
ஏன் இது முக்கியம்The margin expansion to 27% and the 24% growth in CRO indicate high-value service delivery and strong relationships with 19 of the top 25 global pharma firms, supporting the company's premium valuation.
📅 குறுகிய காலம்The stock may react positively to the 22% PAT growth and margin expansion, confirming the company's ability to maintain its guidance.
📈 நீண்ட காலம்The structural shift toward integrated CRDMO services and a 26% 5-year revenue CAGR position the company well for long-term growth in the global pharma outsourcing market.
⚠ அபாய எச்சரிக்கைகள்
Volatility in global biotech funding impacting CRO segment visibility
High capex intensity requiring sustained execution to maintain ROCE
Forex fluctuations (₹1 Cr loss in Q1 vs ₹4 Cr gain YoY)
👀 கவனிக்க வேண்டியவை
Watch for the execution of the new 100,000 sq. ft. R&D facility in Hyderabad and the conversion of 14 late-phase molecules into commercial revenue streams.
Rs 546.7 Cr Revenue in Q1; PAT Grows 22% YoY but Dips 30% Sequentially
Sai Life Sciences reported a standalone revenue of Rs 546.73 Cr for Q1 FY27, marking a 13.2% growth compared to the same quarter last year. Net profit for the quarter stood at Rs 71.34 Cr, up 22.2% YoY, but significantly lower than the Rs 102.53 Cr recorded in the preceding March quarter. The company maintained its focus on the CRDMO segment, though other income saw a sharp decline to Rs 3.54 Cr from Rs 10.01 Cr YoY. Additionally, the company expanded its equity base by allotting 5.06 lakh shares through ESOP exercises.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned into the new financial year with moderate YoY growth but a sequential contraction in profitability and revenue compared to Q4 FY26.
ஏன் இது முக்கியம்For a high-valuation company (P/E 85.3), consistent sequential growth is often expected; the current QoQ dip may lead to a period of consolidation despite the healthy YoY improvement.
📅 குறுகிய காலம்The stock may face some pressure or trade sideways in the short term due to the sequential decline in profit and revenue.
📈 நீண்ட காலம்The long-term outlook remains tied to the scaling of late-stage programs and the integrated CRDMO model, which targets 15-20% growth.
⚠ அபாய எச்சரிக்கைகள்
Sequential decline in earnings
High P/E valuation relative to growth
Volatility in biotech funding impacting CRO segment
👀 கவனிக்க வேண்டியவை
Monitor the company's ability to sustain its target EBITDA margins of 28-30% in upcoming quarters. Investors should track the progress of the three products recently moved to the late-stage pipeline, as these are critical for commercial-scale revenue growth.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Sai Life Sciences FY26 PAT Jumps 109% to ₹355 Cr; Plans Massive ₹1,100-1,300 Cr Capex for FY27
Sai Life Sciences delivered a stellar performance in FY26, with consolidated revenue growing 29% YoY to ₹2,192 crore. Profitability saw a significant surge as PAT doubled to ₹355 crore, while EBITDA margins expanded by 508 bps to reach 30.1% due to strong operating leverage. The company has announced an aggressive front-loaded Capex plan of ₹1,100-1,300 crore for FY27 to support long-term demand from global pharma clients. Management has guided for a 15-20% revenue CAGR over the next 3-5 years with sustained margins of 28-30%.
முக்கிய அம்சங்கள்
Consolidated revenue grew 29% YoY to ₹2,192 Cr, with the CDMO segment contributing 65% of total sales.EBITDA increased 56% YoY to ₹661 Cr, with margins improving from 25.1% to 30.1%.PAT surged 109% YoY to ₹355 Cr, reflecting high operational efficiency and growth in high-margin discovery services.Planned FY27 Capex of ₹1,100-1,300 Cr is nearly double the FY26 spend, with 70% allocated to capacity expansion.Maintains a strong portfolio with 34 active NCE commercial molecules and relationships with 19 of the top 25 global pharma companies.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's aggressive capacity expansion and its ability to maintain 30% margins despite heavy investments. The stock remains a strong play in the Indian CRDMO space given its deep integration with global big pharma and robust 15-20% growth guidance.
Sai Life Sciences Reports Strong FY26 Growth with 29% Revenue Rise and 29.8% EBITDA Margin
Sai Life Sciences has disclosed its Key Performance Indicators (KPIs) for the period FY22 to FY26, showcasing a robust growth trajectory. Revenue from operations increased significantly to 21,924.92 million in FY26, representing a 29.38% YoY growth. Profitability has seen a massive surge, with PAT margins expanding from 5.65% in FY24 to 15.91% in FY26. Additionally, the company has effectively deleveraged its balance sheet, with the Net Debt/Equity ratio dropping to 0.01 in FY26 from 0.75 in FY24.
முக்கிய அம்சங்கள்
Revenue from operations grew 29.38% YoY to 21,924.92 million in FY26.EBITDA margin expanded significantly to 29.78% in FY26, up from 20.48% in FY24.PAT surged to 3,489.10 million in FY26, marking a 105.08% YoY growth.Net Debt/Equity ratio improved to 0.01 in FY26 from 0.75 in FY24, indicating strong deleveraging.Operational efficiency improved with Net Working Capital days reducing to 86 days in FY26 from 122 days in FY24.
👀 கவனிக்க வேண்டியவை
The company demonstrates exceptional fundamental growth and margin expansion, making it a strong contender in the CDMO/Life Sciences space. Investors should closely watch for upcoming listing or IPO developments as the financial health has improved drastically over the last three years.
Sai Life Sciences FY26 Net Profit Doubles to ₹355 Cr; EBITDA Margins Expand to 30%
Sai Life Sciences reported a stellar performance for FY26, with annual revenue growing 29% to ₹2,192 crore. The company's profitability saw a significant boost, with EBITDA rising 56% and Net Profit doubling to ₹355 crore. EBITDA margins improved significantly from 25% in FY25 to 30% in FY26, driven by operational efficiencies and a shift towards integrated discovery services. Despite a modest 4% revenue growth in Q4, the full-year trajectory remains strong with a substantial ₹633 crore capital expenditure investment for future growth.
முக்கிய அம்சங்கள்
Full-year FY26 Revenue grew 29% YoY to ₹2,192 Cr, while Q4 Revenue rose 4% to ₹602 Cr.EBITDA for FY26 surged 56% to ₹661 Cr, with margins expanding by 500 bps to 30%.Net Profit (PAT) for the full year more than doubled, reaching ₹355 Cr compared to ₹170 Cr in FY25.The company incurred a significant Capex of ₹633 Cr to expand integrated CRDMO capabilities and next-gen technologies.Growth was primarily driven by deepening engagement with large pharma and momentum in integrated discovery services.
👀 கவனிக்க வேண்டியவை
Investors should focus on the significant margin expansion and the doubling of net profit as indicators of strong operational leverage. The substantial Capex investment suggests a robust pipeline and management's confidence in long-term demand within the CRDMO sector.
Sai Life Sciences FY26 PAT Jumps 97% to ₹3,415 Mn; Annual Revenue Up 31%
Sai Life Sciences delivered a robust performance for the financial year ended March 31, 2026, with annual revenue from operations growing 31.1% YoY to ₹21,532.26 million. The company's net profit (PAT) nearly doubled during the year, reaching ₹3,414.81 million compared to ₹1,734.62 million in FY25. For the final quarter (Q4 FY26), revenue grew 4.8% YoY to ₹5,943.40 million, while PAT increased by 14% to ₹1,025.32 million. The company also showed strong operational efficiency with net cash from operating activities rising to ₹4,952.69 million.
முக்கிய அம்சங்கள்
Full-year FY26 Revenue from operations increased by 31.1% YoY to ₹21,532.26 million.Annual Net Profit (PAT) surged by 96.9% YoY to ₹3,414.81 million from ₹1,734.62 million.Basic Earnings Per Share (EPS) for FY26 rose to ₹16.27 from ₹9.00 in FY25.Net cash generated from operating activities improved significantly to ₹4,952.69 million.Property, Plant and Equipment assets increased to ₹14,808.39 million, reflecting major capacity expansion.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin expansion and doubling of profits, which indicate strong operational leverage. The substantial increase in fixed assets and capital work-in-progress suggests the company is positioning itself for continued growth in the coming years.
Sai Life Sciences Achieves 100% Renewable Power at Bidar Campus; First Indian CRDMO to do so
Sai Life Sciences has successfully transitioned its Bidar campus, including its flagship API and animal health facilities, to 100% renewable electricity. This milestone makes it the first Indian CRDMO to achieve such a feat at a site level, with 97% of power sourced directly from solar and wind. On an organizational level, nearly 80% of total electricity consumption is now renewable, resulting in zero market-based Scope 2 emissions. This transition avoids approximately 35,110 metric tonnes of CO2 emissions annually, significantly enhancing the company's ESG profile for global innovator clients.
முக்கிய அம்சங்கள்
Bidar campus (Units IV and VI) reached 100% renewable electricity usage in FY26Renewable energy share increased from 21% in 2020 to 89% in FY24 and 100% in FY26Company-wide renewable energy consumption has reached nearly 80%Avoids an estimated 35,110 metric tonnes of CO2 emissions annuallyInfrastructure includes a 2.7 MW wind project under a group captive model
👀 கவனிக்க வேண்டியவை
Investors should recognize this as a significant ESG milestone that strengthens the company's competitive position with global pharmaceutical innovators. While not a direct financial metric, such sustainability achievements are increasingly critical for long-term contract wins and operational resilience.
Sai Life Sciences Receives GST Demand Order of INR 32.86 Crore
Sai Life Sciences Limited has received an order from the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi, regarding GST discrepancies for the financial year 2021-22. The total demand amounts to INR 32.86 crore, which includes IGST, interest, and penalties. The issue stems from alleged excess Input Tax Credit (ITC) claims in GSTR-3B compared to GSTR-2A. The company has stated it will file an appeal at the Tribunal level and does not expect a material financial impact.
முக்கிய அம்சங்கள்
Total tax demand of INR 32.86 crore issued by Karnataka tax authoritiesDemand includes IGST of INR 16.28 crore and interest of INR 13.32 crorePenalty of INR 3.26 crore imposed for alleged excess ITC claims in FY 2021-22Company intends to contest the order by filing an appeal with the Tribunal
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the upcoming appeal as the demand represents a significant one-time liability. While the company expects a favorable outcome, any adverse ruling at the Tribunal level could impact short-term cash flows.
Sai Life Sciences Appoints Dr. John Pavey as Head of Global PR&D Effective April 1, 2026
Sai Life Sciences has announced a planned leadership transition within its Senior Management Personnel. Dr. John Pavey will take over as Head of Global Process Research and Development (PR&D) effective April 1, 2026, succeeding Dr. Dean David Edney who retires on March 31, 2026. Dr. Pavey brings over 20 years of global experience from top-tier pharmaceutical companies including Johnson & Johnson and AstraZeneca. This move ensures continuity in the company's critical R&D functions with a highly experienced industry veteran.
முக்கிய அம்சங்கள்
Dr. John Pavey appointed as Senior Management Personnel (SMP) effective April 1, 2026Dr. Dean David Edney to retire from the Head of Global PR&D role on March 31, 2026Incoming leader Dr. Pavey has over 20 years of experience in CMC and chemical developmentDr. Pavey's career includes senior roles at Johnson & Johnson, UCB, and AstraZenecaTransition focuses on maintaining expertise in API development, regulatory approvals, and sustainable manufacturing
👀 கவனிக்க வேண்டியவை
This is a routine management succession and should be viewed as a neutral event. Investors should monitor if the new leadership brings any strategic shifts to the company's R&D service offerings.
ICRA Assigns [ICRA]AA (Stable) and [ICRA]A1+ Ratings to Sai Life Sciences' Rs 768.60 Cr Debt
ICRA Limited has assigned high-grade credit ratings to Sai Life Sciences Limited for its total debt facilities of Rs 768.60 crore. The long-term fund-based facilities of Rs 550 crore received an [ICRA]AA (Stable) rating, while short-term non-fund-based facilities of Rs 218.60 crore were assigned [ICRA]A1+. These ratings reflect a strong credit profile and a high degree of safety regarding the timely servicing of financial obligations. The facilities are spread across major lenders including State Bank of India, IndusInd Bank, and Bank of Baroda.
முக்கிய அம்சங்கள்
Assigned [ICRA]AA (Stable) rating for Rs 550.00 crore long-term fund-based facilitiesAssigned [ICRA]A1+ rating for Rs 218.60 crore short-term non-fund-based facilitiesTotal rated debt instruments amount to Rs 768.60 crore across multiple banking partnersState Bank of India holds the largest share of rated limits at Rs 230.60 croreThe 'Stable' outlook indicates ICRA's expectation of maintained credit quality in the medium term
👀 கவனிக்க வேண்டியவை
Investors should view these high investment-grade ratings as a sign of financial robustness and low credit risk. No immediate action is required, but the ratings support a positive long-term outlook for the company's capital structure.
Sai Life Sciences Q3 FY26 PAT Surges 86% to ₹100 Cr; EBITDA Margins Expand to 34.4%
Sai Life Sciences reported a strong performance for Q3 FY26, with consolidated revenue growing 27% YoY to ₹556 crore. The company's profitability saw a significant boost as EBITDA rose 54% to ₹191 crore, driven by a 605 bps margin expansion to 34.4%. For the nine-month period, PAT grew by a massive 199% to ₹245 crore, reflecting robust operational leverage and healthy demand in the CDMO segment. The company is aggressively investing in capacity, with ₹405 crore of the planned ₹700 crore FY26 capex already deployed.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue increased 27% YoY to ₹556 crore, with CDMO services contributing 65% of total revenue.EBITDA margins expanded significantly by 605 bps to 34.4%, outperforming the company's long-term guidance of 28-30%.Net Profit (PAT) for the quarter jumped 86% YoY to ₹100 crore, while 9M FY26 PAT grew 199% to ₹245 crore.Added 7 molecules to the late-phase and commercial pipeline during the year, taking the total to 43 molecules.Invested ₹405 crore in capital expenditure out of a ₹700 crore plan for FY26 to expand manufacturing capacity by ~450KL.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's execution of its ₹700 crore capex plan and its ability to maintain margins above 30% as new capacities come online. The strong pipeline growth in late-phase molecules provides good revenue visibility for the coming years.
Sai Life Sciences Q3 FY26 PAT Jumps 91% YoY to ₹976.3 Million; Revenue Up 28%
Sai Life Sciences reported a robust performance for the quarter ended December 31, 2025, with revenue from operations growing 28.1% YoY to ₹5,491.79 million. Net profit surged by 91.2% YoY to ₹976.30 million, even after accounting for a one-time exceptional loss of ₹82.93 million due to new labor code liabilities. The company has successfully utilized its entire IPO proceeds of ₹9,098.84 million, primarily for debt repayment, which has significantly reduced finance costs from ₹216.59 million to ₹80.61 million YoY. Operational efficiency is reflected in the Profit Before Tax, which grew 92.1% YoY to ₹1,304.69 million.
முக்கிய அம்சங்கள்
Revenue from operations increased 28.1% YoY to ₹5,491.79 million from ₹4,286.02 million.Net Profit (PAT) grew 91.2% YoY to ₹976.30 million compared to ₹510.57 million in the previous year.Finance costs significantly decreased to ₹80.61 million from ₹216.59 million YoY following debt repayment.Exceptional loss of ₹82.93 million recorded due to increased gratuity and leave liabilities under new Labour Codes.Fully utilized IPO proceeds of ₹9,098.84 million, with ₹7,200 million used for debt repayment.
👀 கவனிக்க வேண்டியவை
The strong top-line growth and significant reduction in interest costs post-IPO debt repayment make this a positive result. Investors should monitor if the company can maintain these improved margins as it scales operations.
Sai Life Sciences Partners with Mabtech to Launch Immunology Research Hub in Boston
Sai Life Sciences has announced a strategic collaboration with Swedish firm Mabtech to establish its Boston laboratory as a US execution and demonstration hub for the EYRA platform. This partnership enables Sai to offer advanced immunology assay services, including high-sensitivity multiplex cytokine and phenotyping workflows, to global biopharma clients. The EYRA platform allows for the simultaneous detection of dozens of analytes in a single run, significantly enhancing Sai's discovery and translational research capabilities. This move strengthens the company's competitive position in high-growth sectors like immuno-oncology, vaccines, and cellular therapy.
முக்கிய அம்சங்கள்
Sai’s Boston site becomes a co-marketed US execution hub for the Mabtech EYRA platformJoint delivery of advanced immunology services targeting immuno-oncology and cellular therapyEYRA platform enables simultaneous detection of dozens of analytes with minimal hands-on timeStrategic expansion of US discovery operations to accelerate biopharma development timelines
👀 கவனிக்க வேண்டியவை
Investors should monitor the impact of this high-tech service expansion on Sai's US revenue growth and client acquisition. This collaboration enhances the company's value proposition in the specialized CRDMO market.
Sai Life Sciences Receives GST Penalty Order of ₹4.93 Crore for FY 2018-22
Sai Life Sciences Limited has received a tax order from the Additional Commissioner, Ranga Reddy GST Commissionerate, imposing a penalty of ₹4.93 crore. The demand is based on alleged excess Input Tax Credit (ITC) availment and discrepancies between B2B supply records and government portal data for the period FY 2018-19 to FY 2021-22. The company has stated its intention to file an appeal against this order, expressing confidence in a favorable outcome. While the penalty is significant, the company does not currently expect a material financial impact on its operations.
முக்கிய அம்சங்கள்
Penalty of INR 4,93,36,015 (₹4.93 crore) imposed under Section 74 of the CGST/TGST Act.Order relates to alleged excess ITC availment and B2B supply record differences.The investigation covers a four-year period from financial year 2018-19 to 2021-22.Company plans to contest the order through the formal appellate process.Management currently assesses no material financial impact pending the appeal outcome.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the appeal as the penalty amount is noteworthy, though not immediately detrimental to the company's liquidity. No immediate action is required unless the appellate authority upholds the demand.
SAILIFE: Order passed u/s 73(9) of GST Act, demand of ₹32.86 Cr
Sai Life Sciences received an order from the Deputy Commissioner of Commercial Taxes (Audit), Bidar, DGSTO Kalaburagi under Section 73(9) of the Integrated Goods and Services Tax Act, 2017. The order demands ₹16,28,46,397 towards IGST, ₹13,31,50,353 as interest, and ₹3,25,69,279 as penalty, totaling ₹32.86 Cr. The demand relates to alleged excess availment of Input Tax Credit in GSTR-3B compared to GSTR-2A for FY 2021-22. The company plans to file an appeal and anticipates a favorable outcome, expecting no material financial impact.
முக்கிய அம்சங்கள்
IGST demand of ₹16,28,46,397Interest demand of ₹13,31,50,353Penalty of ₹3,25,69,279Order passed under Section 73(9) of the GST ActDemand related to FY 2021-22
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the appeal filed by the company. While the company anticipates a favorable outcome, any adverse development could potentially impact its financials.
SAILIFE: Order passed under GST Act with demand of ₹8.8 Cr
Sai Life Sciences has received an order from the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi under the Karnataka Goods and Services Tax Act, 2017. The order demands IGST of ₹4,62,36,986, Cess of ₹291,659, Interest of ₹3,20,77,995, and a Penalty of ₹92,76,563, totaling approximately ₹8.8 crores. The demand relates to alleged excess availment of ITC and discrepancies in B2B supply records for FY 2020-21. The company plans to appeal the order and anticipates a favorable outcome, expecting no material financial impact.
முக்கிய அம்சங்கள்
IGST demand of ₹4,62,36,986Cess demand of ₹291,659Interest demand of ₹3,20,77,995Penalty of ₹92,76,563 imposedOrder passed under Section 107 (11) of the GST Act, 2017
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the appeal process. While the company expects a favorable outcome, any adverse ruling could potentially impact its financials.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
